Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioRestorative Therapies Inc BRTX

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured... see more

Recent & Breaking News (NDAQ:BRTX)

BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data

GlobeNewswire November 13, 2024

BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 12, 2024

BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium

GlobeNewswire November 6, 2024

BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health

GlobeNewswire November 5, 2024

BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program

GlobeNewswire October 31, 2024

BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

GlobeNewswire October 10, 2024

BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire October 3, 2024

BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs

GlobeNewswire September 19, 2024

BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 13, 2024

BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024

GlobeNewswire August 6, 2024

BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine

GlobeNewswire July 23, 2024

BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

GlobeNewswire June 27, 2024

BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results

GlobeNewswire June 17, 2024

BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program

GlobeNewswire June 13, 2024

BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference

GlobeNewswire June 4, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice

GlobeNewswire May 24, 2024

BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Accesswire May 15, 2024

BioRestorative Therapies Provides First Quarter 2024 Business Update

GlobeNewswire May 14, 2024

BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

GlobeNewswire May 8, 2024

BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

GlobeNewswire April 30, 2024